NCT03578367 2025-11-10
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Novartis
Phase 2 Completed
Novartis
Gruppo Italiano Malattie EMatologiche dell'Adulto
Novartis
Novartis
Emory University
Cancer Trials Ireland